Medication info
Trajuno Sustained-release Tablets 5/1000 mg (Linagliptin, Metformin)

Trajuno Sustained-release Tablets 5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
Pink oval film-coated sustained-release tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202400691 · Approved 2024.03.29 · Insurance code 642106210

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, patients taking linagliptin 5 mg and metformin hydrochloride (extended-release) 1000 mg may take 1 tablet once daily with a meal. To reduce gastrointestinal adverse reactions associated with metformin, this medicine should be taken once daily with a meal, preferably in the evening. To maintain its extended-release properties, this medicine must be swallowed whole and not split, crushed, ground, or chewed. Because dosage adjustment may be needed according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥45mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≥45mL/min/1.73m2 and <60mL/min/1.73m2, this medicine may be used with dose adjustment of metformin hydrochloride as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to improve blood sugar control in patients with Type 2 diabetes. Linagliptin and Metformin work together to effectively lower blood sugar levels and support dietary and exercise therapies. This allows for more stable blood sugar management, helping to improve the health of patients.

How to take

Adult dose

For antidiabetic therapy, patients taking linagliptin 5 mg and metformin hydrochloride (extended-release) 1000 mg may take 1 tablet once daily with a meal. To reduce gastrointestinal adverse reactions associated with metformin, this medicine should be taken once daily with a meal, preferably in the evening. To maintain its extended-release properties, this medicine must be swallowed whole and not split, crushed, ground, or chewed. Because dosage adjustment may be needed according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥45mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≥45mL/min/1.73m2 and <60mL/min/1.73m2, this medicine may be used with dose adjustment of metformin hydrochloride as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication is an anti-diabetic agent containing two main components: Linagliptin and Metformin. Firstly, Metformin can rarely cause a serious metabolic disorder called lactic acidosis, which can be life-threatening if not treated immediately. Secondly, this medication should not be used in certain patients, such as those allergic to this medication or in patients with Type 1 diabetes, severely impaired kidney function, acute infections or severe dehydration, and those with liver dysfunction. Thirdly, there is a risk of hypoglycemia, so caution is warranted when used with other hypoglycemic agents such as insulin or sulfonylureas, and dosage adjustments may be necessary as needed. Fourthly, kidney function significantly impacts the safety and efficacy of this medication, thus regular kidney function tests should be conducted before and during treatment, and this medication should not be used in cases of impaired kidney function. Fifthly, this medication should be temporarily discontinued around acute surgeries or examinations using radioactive iodine contrast agents, and can only be resumed after kidney function returns to normal. Sixthly, it is advisable not to use this medication during pregnancy, and it is also safe to avoid use while breastfeeding. Seventhly, long-term use may lead to Vitamin B12 deficiency, so Vitamin B12 levels should be monitored regularly as needed. Eighthly, taking this medication with alcohol may increase the risk of lactic acidosis, hence alcohol consumption should be avoided. Ninthly, if abdominal pain, persistent vomiting, breathing difficulties, muscle weakness, severe skin rashes or blisters occur, immediate consultation with a physician is required. Finally, this medication must be swallowed whole without chewing, breaking, crushing, or chewing the tablet, and it is normal for the shell of the tablet to be excreted in the stool.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption test
  • hypoglycemia
  • taste disorder
  • cough
  • loss of appetite
Show 122 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulceration
  • abnormal liver function test
  • hepatitis
  • itching
  • erythema
  • rash
  • pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity reaction
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer-type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage kidney disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • chest discomfort
  • weakness
  • pain
  • epistaxis
  • oropharyngeal pain
  • dysphonia
  • nasal bleeding
  • wet cough
  • rhinorrhea
  • pulmonary mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • increased serum triglycerides
  • increased urine albumin/creatinine ratio
  • positive urine leukocytes
  • decreased hemoglobin
  • increased serum potassium
  • increased serum creatinine
  • increased serum creatine phosphokinase
  • elevated ALT
  • male pattern baldness
  • hyperhidrosis
  • dermatitis
  • diabetic foot disease
  • dermatitis
  • anxiety
  • confusional state
  • nocturia
  • dermatitis
  • hypertension
  • benign prostatic hyperplasia
  • vitreous hemorrhage
  • erectile dysfunction
  • goiter
  • myelodysplastic syndrome
  • flank pain
  • ligament sprain
  • vocal cord polyp

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, and it is safe to store it at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain its effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Pink oval film-coated sustained-release tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.